7/29, 10:05 PM (Source: TeleTrader)
more TeleTrader news

Gilead posts Q2 revenue at $6.2B, up 21% YoY

Gilead Sciences Inc. on Thursday announced its second-quarter revenue climbed 21% to $6.15 billion. Total costs and expenses were down 105% to $3.97 billion. Net income jumped from negative territory to $1.52 billion, while earnings per share grew to $1.21.

The pharma company updated its guidance for full-year revenue to between $24.4 billion and $25.0 billion from between $23.7 billion and $25.1 billion. EPS is seen coming in between $4.70 and $5.05, compared to $4.75 to $5.45 previously.

"We maintained our positive momentum in the second quarter, with both a solid financial performance and strong progress across our increasingly diverse portfolio. Our flagship HIV therapy, Biktarvy, saw continued growth and gains in market share, despite the ongoing impact of the pandemic," CEO Daniel O'Day said.

Breaking the News / MD